Lafutizene Tablet 10mg (Lafutidine)

Adult dosage

1. Short-term treatment of gastric ulcers: The usual dose is 10mg of lafutidine orally twice daily, in the morning and at bedtime. In clinical trials in which treatment was given for up to 8 weeks, most ulcers healed within 8 weeks, although the healing period may occasionally vary from patient to patient. 2. Short-term treatment of duodenal ulcers: The usual dose is 10mg of lafutidine orally twice daily, in the morning and at bedtime. In clinical trials in which treatment was given for up to 6 weeks, most ulcers healed within 6 weeks, although the healing period may occasionally vary from patient to patient. 3. Improvement of gastric mucosal lesions in acute and chronic gastritis: The usual dose is 10mg of lafutidine orally once daily at bedtime. In clinical trials in which treatment was given for up to 2 weeks, most lesions healed within 2 weeks, although the healing period may occasionally vary from patient to patient. 4. Combination therapy with antibiotics in patients with peptic ulcers infected with Helicobacter pylori: Administer 20mg of lafutidine, 500mg of clarithromycin, and 1000mg of amoxicillin twice daily for 7 or 14 days. 5. Premedication: The usual dose is 10mg of lafutidine orally per dose, for 2 doses (at bedtime on the day before surgery and 2 hours before administration of anesthesia on the day of surgery). 6. Treatment of reflux esophagitis: Administer 10mg of lafutidine orally twice daily.

This medication should not be taken by individuals allergic to any of its components. It contains lactose, so individuals with a genetic inability to digest lactose should not take this medication. Those with a history of drug allergies should take this medication with caution, and individuals with liver or kidney function issues should also be careful. Particularly, patients undergoing dialysis and the elderly should exercise greater caution when taking this medication. This medication can rarely cause severe allergic reactions, liver dysfunction, or reduction in blood cell count; if such symptoms occur, discontinue use immediately and consult a healthcare professional. Headache, dyspepsia, constipation, diarrhea, nausea, vomiting, and abdominal bloating may occur; if symptoms are severe or persistent, consult a physician. Symptoms of malignancy may be concealed while taking this medication, therefore, if there are symptoms such as weight loss, recurrent vomiting, or hematemesis, it is essential to undergo examination. Elderly patients may have decreased bodily function; thus, dosage and intervals should be adjusted carefully, and their condition should be monitored closely. Women who are pregnant or may become pregnant should take this medication under a doctor's discretion, and breastfeeding women should avoid it as it may be excreted in breast milk. The safety of this medication in children has not been fully established, so it is advisable not to use it in children. This medication should be stored out of reach of children and should be kept in its original container to maintain the quality of the medication.

• Shock
• Anaphylactic symptoms
• Facial pallor
• Hypotension
• Systemic rash
• Dyspnea
• Hepatic dysfunction
• Jaundice
• Agranulocytosis
• Pharyngitis

This medication should be stored in a tightly closed container to prevent air or moisture from entering. Additionally, avoid storing it in excessively hot or cold places, and it is best to keep it at room temperature between 1°C and 30°C.

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle